CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)
- FinancialsAltman Z-Score 14.03: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.69%Below 5Y avg (1.42%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
50.0%Sustainable
Last Ex-Dividend
Jul 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.78BCNY564.22M · vs all stocks (USD)
Trailing P/E
47.83xvs Biotechnology peers
Revenue (TTM)
372.08MCNY55.52M · vs all stocks (USD)
Profit Margin
21.07%vs Biotechnology peers
Beta
0.2360xvs all stocks
52-Week Change
-18.52%vs all stocks
Market Capitalization
3.78BCNY564.22M · vs all stocks (USD)
Enterprise Value
3.09BCNY461.67M · vs all stocks (USD)
Trailing P/E
47.83xvs Biotechnology peers
Forward P/E
28.14xvs Biotechnology peers
Price to Sales (TTM)
10.16xvs Biotechnology peers
Price to Book (MRQ)
2.11xvs Biotechnology peers
Enterprise to Revenue
8.31xvs Biotechnology peers
Enterprise to EBITDA
36.42xvs Biotechnology peers
Gross Margin
48.78%vs Biotechnology peers
Profit Margin
21.07%vs Biotechnology peers
Operating Margin
4.16%vs Biotechnology peers
Return on Assets (TTM)
1.51%vs Biotechnology peers
Return on Equity (TTM)
4.38%vs Biotechnology peers
Revenue (TTM)
372.08MCNY55.52M · vs all stocks (USD)
Revenue per Share (TTM)
1.44CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-1.40%vs Biotechnology peers
Gross Profit (TTM)
187.59MCNY27.99M · vs all stocks (USD)
EBITDA (TTM)
71.18MCNY10.62M · vs all stocks (USD)
Net Income (TTM)
78.41MCNY11.70M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-51.40%vs Biotechnology peers
Operating Cash Flow (TTM)
105.72MCNY15.78M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-40.58MCNY-6.05M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.69%vs all stocks
5-Year Average Dividend Yield
1.42%vs all stocks
Payout Ratio
50.00%vs Biotechnology peers
Revenue
365.92MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
177.46MCNYFY2025 · Dec 31, 2025Gross Profit
188.46MCNYFY2025 · Dec 31, 2025Operating Income
84.40MCNY12.59M · vs all stocks (USD)
Pre-tax Income
103.83MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.31MCNYFY2025 · Dec 31, 2025Net Income
94.52MCNYFY2025 · Dec 31, 2025EBIT
103.97MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
139.39MCNYFY2025 · Dec 31, 2025Research & Development
35.71MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
35.62MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.57MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
19.87MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
144.43KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3600CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
262.55MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
262.55MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
94.52MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
42.16MCNYFY2025 · Dec 31, 2025Free Cash Flow
-253.96MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
99.65MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
94.52MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-18.55MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-26.42MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.40MCNYFY2025 · Dec 31, 2025Capital Expenditures
-296.12MCNYFY2025 · Dec 31, 2025Purchase of Investments
-896.88MCNYFY2025 · Dec 31, 2025Sale of Investments
1.10BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-88.97MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-39.52MCNYFY2025 · Dec 31, 2025Other Financing Charges
-889.27KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-40.41MCNYFY2025 · Dec 31, 2025Shares Outstanding
263.50MSharesUpdated Sep 21, 2026Float Shares
142.88MSharesUpdated Sep 21, 2026% Held by Insiders
47.96%vs all stocks
% Held by Institutions
9.31%vs all stocks
Total Cash (MRQ)
690.76MCNY103.07M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.62CNYUpdated Sep 21, 2026Total Debt (MRQ)
3.51MCNY523.33K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0020xvs Biotechnology peers
Current Ratio (MRQ)
4.54xvs Biotechnology peers
Book Value per Share (MRQ)
6.80CNYUpdated Sep 21, 2026Total Assets
2.02BCNY301.26M · vs all stocks (USD)
Total Current Assets
977.34MCNYFY2025 · Dec 31, 2025Total Liabilities
176.08MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.04BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
48.48MCNYFY2025 · Dec 31, 2025Total Current Liabilities
127.60MCNYFY2025 · Dec 31, 2025Cash
98.05MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.65MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
99.70MCNYFY2025 · Dec 31, 2025Other Short-term Investments
110.21MCNYFY2025 · Dec 31, 2025Accounts Receivable
69.06MCNYFY2025 · Dec 31, 2025Inventory
46.47MCNYFY2025 · Dec 31, 2025Accounts Payable
88.08MCNYFY2025 · Dec 31, 2025Short-term Debt
785.07KCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.16MCNYFY2025 · Dec 31, 2025Long-term Debt
2.80MCNYFY2025 · Dec 31, 2025Common Stock (Book)
263.50MCNYFY2025 · Dec 31, 2025Retained Earnings
414.82MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.84BCNY274.99M · vs all stocks (USD)
52-Week Low
13.02CNYUpdated Sep 21, 202652-Week High
27.08CNYUpdated Sep 21, 202652-Week Change
-18.52%vs all stocks
Beta
0.2360xvs all stocks
50-Day MA
14.45CNYUpdated Sep 21, 2026200-Day MA
16.69CNYUpdated Sep 21, 2026Avg 10-Day Volume
2.46MSharesUpdated Sep 21, 2026Avg 30-Day Volume
4.56MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.3000CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Financial Health
Altman Z-Score 14.03: safe zoneNotable
Altman Z-Score: 14.03
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Nanjing Well Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neurogene Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Starry Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gujarat Themis Biosyn Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Hicin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Allogene Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Orient Gene Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Monopar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Transtek Medical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule